AstraZeneca (AZN) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
AZN Community Fair Values
Create NarrativeSee what 280 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£139.48 |
| 52 Week High | UK£157.32 |
| 52 Week Low | UK£96.51 |
| Beta | 0.28 |
| 1 Month Change | -5.05% |
| 3 Month Change | 2.56% |
| 1 Year Change | 31.49% |
| 3 Year Change | 17.70% |
| 5 Year Change | 81.61% |
| Change since IPO | 2,000.60% |
Recent News & Updates
Recent updates
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook
Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating
Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns
AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects
AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes
AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest
Nov 13
AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance
AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success
AstraZeneca's analyst price target has been raised from £138.16 to £140.96. This reflects a modest increase as analysts highlight both expanding potential for key pipeline products and a tempered outlook on patent risk and competitive pressures in certain therapeutic areas.Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success
AstraZeneca’s analyst price target has been raised from $93 to $99. Analysts cite stronger pipeline progress and improved revenue growth forecasts as key factors for the upward revision.Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success
Despite ongoing pipeline successes that support long-term topline growth, the consensus price target for AstraZeneca has been revised slightly lower to £134.64 due to concerns over execution in recent Wainua sales. Analyst Commentary Bullish analysts have raised long-term revenue forecasts for AstraZeneca due to substantial pipeline progress year-to-date, expecting stronger topline growth through 2030.Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success
Despite ongoing pipeline progress and bullish long-term forecasts, AstraZeneca’s consensus price target was revised modestly downward to £135.55, as analysts balanced positive R&D developments against short-term revenue headwinds and market reactions. Analyst Commentary Bullish analysts increased long-term revenue forecasts, citing substantial pipeline progress achieved this year.Shareholder Returns
| AZN | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -3.8% | -4.5% | -0.9% |
| 1Y | 31.5% | 24.5% | 21.7% |
Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned 24.5% over the past year.
Return vs Market: AZN exceeded the UK Market which returned 21.7% over the past year.
Price Volatility
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: AZN has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
AstraZeneca PLC Fundamentals Summary
| AZN fundamental statistics | |
|---|---|
| Market cap | UK£216.33b |
| Earnings (TTM) | UK£7.64b |
| Revenue (TTM) | UK£44.43b |
Is AZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZN income statement (TTM) | |
|---|---|
| Revenue | US$60.44b |
| Cost of Revenue | US$11.18b |
| Gross Profit | US$49.26b |
| Other Expenses | US$38.87b |
| Earnings | US$10.39b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 27, 2026
| Earnings per share (EPS) | 6.70 |
| Gross Margin | 81.50% |
| Net Profit Margin | 17.19% |
| Debt/Equity Ratio | 68.4% |
How did AZN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 10:23 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca PLC is covered by 59 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |